AI in Clinical Trials Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

The global AI in clinical trials market was valued at USD 2.34 Billion in 2025. It is poised to grow at a CAGR of 14.00% during the forecast period of 2026-2035, and reach USD 8.67 Billion by 2035. The market growth is driven by rising R&D costs, demand for faster patient recruitment, improved trial efficiency, real-world data integration, regulatory support, and increasing adoption of predictive analytics.

Q1 2026 Market Updates

Geopolitical Impact of Iran, US, and Israel War on the AI in Clinical Trials Market

United States: The AI in Clinical Trials Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. Petrochemical-derived pharmaceutical packaging materials including blister packs, polymer bottles, and specialty film coatings are facing 15-20% cost inflation from the Gulf supply disruption. API production costs are rising as petrochemical reagent prices increase 15-20%. Air freight costs have spiked dramatically, with temperature-sensitive pharmaceutical distribution facing elevated costs and extended lead times as Gulf carrier networks remain suspended. Consumer spending caution is growing as gasoline above USD 4 per gallon and 4.2% projected inflation compress household discretionary budgets. Clinical trial operations in Middle Eastern investigator sites have been disrupted, and medical supply chains face elevated logistics costs.

Iran: Iran's healthcare system has been severely damaged by the conflict, with the WHO identifying at least 13 health facilities as conflict-damaged. The domestic pharmaceutical and medical device sector, already severely constrained by sanctions limiting access to Western medical technology and APIs, has been further disrupted by power outages, workforce displacement, and the collapse of medical supply chain logistics. Iranian patients requiring treatment for ai in clinical trials conditions face an acute access crisis, as hospital operations are redirected toward treating conflict casualties and basic medical supplies are running low.

Israel: Israel's pharmaceutical and medical device sector is operating under emergency conditions. Israeli hospitals have moved some operations underground, medical resources are being prioritised for conflict casualties, and elective and non-emergency healthcare consumption has declined. However, Israel's biopharmaceutical research base continues to operate, with several Israeli companies involved in novel treatment development for ai in clinical trials indications. Post-conflict, Israel's healthcare system is expected to invest significantly in medical technology and pharmaceutical infrastructure restoration and capacity expansion.

Key Takeaways

Government

• Relevant health authorities should activate emergency pharmaceutical supply chain resilience protocols, ensuring that API and packaging material sourcing for essential ai in clinical trials treatments is not concentrated in Gulf-adjacent supply chains exposed to maritime disruption.
• Regulatory agencies should fast-track review of treatment availability and consider emergency compassionate use extensions for patients in conflict-affected regions who face interruption to their standard of care.
• Governments should monitor petrochemical-derived pharmaceutical packaging cost inflation, ensuring that price increases remain within access thresholds for patients requiring ongoing ai in clinical trials treatment.

Market

• Petrochemical-derived pharmaceutical packaging and API precursor costs are rising 15-20%, creating margin compression for ai in clinical trials manufacturers in the near term, with limited ability to pass costs through in price-regulated markets.
• The conflict's disruption to clinical trial infrastructure in Middle Eastern sites may modestly delay regulatory submissions and new treatment launches that had enrolled patients from the region, though the structural market growth trajectory remains intact.
• Healthcare system demand for ai in clinical trials treatment is fundamentally driven by disease burden and demographics rather than geopolitical events, providing strong structural insulation for the market's long-term growth trajectory.

Procurement

• Pharmaceutical procurement teams should build 90-day safety stock for essential ai in clinical trials treatment drugs and biological agents, hedging against further pharmaceutical logistics cost increases and potential supply disruptions.
• API and excipient buyers should review single-source supplier risks for Gulf-adjacent petrochemical-derived pharmaceutical inputs, establishing secondary supply arrangements with non-Gulf origin manufacturers in India, China, and Europe.
• Hospital pharmacy procurement managers should review cold-chain logistics contracts for temperature-sensitive ai in clinical trials therapeutics, ensuring that alternative air routing through non-conflict-zone hubs is available if Gulf carrier services remain suspended.

Key Market Trends and Insights

• By phase, the phase II segment dominated the market with around 45% share in the historical period.
• Based on application, the oncology segment held approximately 20% during the historical period.
• The pharmaceutical and biopharmaceutical companies segment consists of nearly 60% during the historical period.

Market Size and Forecast

• Market Size (2025): USD 2.34 Billion
• Projected Market Size (2035): USD 8.67 Billion
• CAGR (2026-2035): 14.00%

AI in Clinical Trials Market Overview

Artificial intelligence (AI) is transforming clinical trials by enhancing patient recruitment, optimizing trial design, and enabling real-time data monitoring. AI-driven analytics improve endpoint selection, reduce protocol deviations, and accelerate decision-making, leading to shorter trial timelines and lower costs. Additionally, AI enhances patient stratification and predictive modeling, improving success rates. Its integration also supports decentralized clinical trials and remote monitoring, increasing accessibility and efficiency. The market reached a value of approximately USD 2.34 Billion in 2025.

AI in Clinical Trials Market Growth Drivers

Regulatory AI Adoption Accelerating Clinical Trial Efficiency and Market Expansion

The growing demand for faster regulatory approvals and increasing adoption of automation in clinical workflows are key market drivers. For instance, in June 2025, the U.S. FDA launched a generative AI tool, “Elsa,” to streamline clinical protocol reviews, safety assessments, and scientific evaluations, significantly improving efficiency. This development is poised to accelerate the market by reducing approval timelines, enhancing data processing capabilities, and encouraging broader adoption of AI-driven regulatory technologies, particularly supporting advancements in trial design optimization during the forecast period.

Strategic AI Collaborations to Propel AI in Clinical Trials Market Value

Rising R&D costs and the need to improve drug development success rates are major growth drivers. For instance, in October 2025, AstraZeneca announced a USD 555 million partnership to leverage AI-driven technologies for identifying immunology drug targets and advancing therapeutic development. This collaboration is expected to boost the market by accelerating early-stage discovery, improving candidate selection, and increasing the efficiency of clinical pipelines, ultimately driving higher adoption of AI-powered solutions, including applications in predictive analytics in clinical trials, during the forecast period.

AI in Clinical Trials Market Trends

Key trends shaping the global market include increasing number of clinical trials and rising demand for data reliability.

Rising Global Clinical Trial Volume Driving AI Adoption and Market Demand

The rapid expansion in global clinical trial activity is a key structural trend accelerating AI adoption. For instance, ClinicalTrials.gov data (updated 2024-2025) shows over 528,000 registered studies globally, with more than 66,000 actively recruiting trials, highlighting increasing complexity in trial management. This surge in trial volume is expected to drive demand for AI-powered solutions to optimize patient recruitment, streamline data management, and enhance trial efficiency, along with increasing adoption of real-world evidence, thereby significantly contributing to market growth during the forecast period.

Regulatory Approvals Strengthening AI Validation and Driving AI in Clinical Trials Market Growth

The increasing demand for standardized endpoints and improved data reliability is a major trend shaping the market. For instance, in March 2025, the European Medicines Agency approved the AIM-NASH AI tool for use in clinical trials, enabling consistent assessment of liver disease severity and improving data validity. This trend is expected to significantly boost market growth by enhancing trial accuracy, reducing variability in human interpretation, and strengthening regulatory confidence in AI-driven clinical evidence generation, particularly through integration with electronic health records (EHR).

AI-Driven Regulatory Integration Transforming Clinical Trial Efficiency and Boosting AI in Clinical Trials Market Development

The rising pressure to shorten drug approval timelines and optimize regulatory workflows is driving AI integration. For instance, in June 2025, the U.S. FDA launched the generative AI tool “Elsa” to streamline clinical protocol reviews, safety evaluations, and scientific assessments. This development is poised to accelerate market expansion by reducing review timelines, improving operational efficiency, and encouraging widespread adoption of AI technologies across clinical trial design, monitoring, and regulatory decision-making processes, including advancements in trial design optimization.

AI in Clinical Trials Market Segmentation

Market Breakup by Phase

• Phase I
• Phase II
• Phase III

Market Breakup by Application

• Oncology
• Neurology Diseases
• Cardiological Diseases
• Infectious Disease
• Immunological Diseases
• Others

Market Breakup by End User

• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• Cancer Centers
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

AI in Clinical Trials Market Share

Oncology Dominates the Application Segment

Based on application segmentation, the oncology segment is expected to hold the largest share of the market, building on its historical contribution of approximately 20%. This dominance is driven by the high complexity of cancer trials, increasing biomarker-driven therapies, and strong demand for precision medicine. AI enables improved patient stratification, faster recruitment, and optimized trial design in oncology. Additionally, the growing oncology pipeline and rising R&D investments by pharmaceutical companies further reinforce the segment’s leading position compared to neurology, cardiology, infectious, and immunological diseases.

AI in Clinical Trials Market Analysis by Region

The market is divided into regions such as North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. Among these, North America is projected to dominate the market in the historical period, accounting for approximately 49% of the total share, driven by advanced healthcare infrastructure, strong presence of leading AI and pharmaceutical companies, and supportive regulatory frameworks. Europe follows with increasing adoption of digital health technologies, while Asia Pacific is expected to witness the fastest growth due to expanding clinical research activities, large patient pools, and rising investments in AI-driven healthcare solutions.

Leading Players in the AI in Clinical Trials Market

The key features of the market report comprise patent analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows

Unlearn.ai, Inc.

Unlearn.ai, Inc., founded in 2017 and headquartered in San Francisco, United States, develops AI-powered “digital twin” technology to optimize clinical trials. Its platform enables intelligent control arms, reducing patient enrollment and accelerating trial timelines. The company collaborates with major pharmaceutical firms and regulators. For instance, in December 2024, Unlearn® achieved significant milestones in advancing AI-driven clinical trial innovation, securing USD 50 million in Series C funding, launching new digital twin-based tools, and expanding strategic partnerships to address challenges such as slow patient enrollment, prolonged trial timelines, and rising development costs in clinical research.

Saama

Saama, established in 1997 and headquartered in Campbell, California, United States, provides AI-driven clinical analytics platforms for life sciences. Its solutions focus on clinical data management, trial optimization, and real-time insights across development phases. The company supports end-to-end clinical operations through its AI-powered platforms. In September 2025, Saama introduced modular Clinical AI Agents, enhancing automation, adaptability, and efficiency across clinical workflows and accelerating drug development processes.

Antidote Technologies, Inc.

Founded in 2010 and headquartered in London, United Kingdom, Antidote Technologies, Inc. specializes in AI-enabled patient recruitment for clinical trials. Its platform connects patients with relevant trials using data-driven matching algorithms, improving enrollment speed and diversity. The company partners with research organizations and patient advocacy groups. Antidote continues expanding its digital recruitment capabilities, addressing one of the most critical bottlenecks in clinical research-patient enrollment efficiency and accessibility.

Phesi

Phesi, founded in 2011 and headquartered in the United States, focuses on AI-driven clinical trial data analytics and simulation. Its Trial Accelerator platform leverages large-scale patient datasets to optimize study design, predict outcomes, and improve recruitment strategies. Phesi supports pharmaceutical companies in reducing trial costs and timelines. In December 2024, the company enhanced its platform with a Patient Burden Score feature, improving protocol design and patient-centric trial planning.

Other key players in the market are Deep6.ai, Innoplexus, Intelligencia AI, Median Technologies, and Consilx.

Key Questions Answered in the AI in Clinical Trials Market

• What was the AI in clinical trials market value in 2025?
• What is the AI in clinical trials market forecast outlook for 2026-2035?
• What major factors aid the demand for AI in clinical trials market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major AI in clinical trials market trends?
• Which phase is expected to dominate the market segment?
• Which application is anticipated to drive the market segment?
• Which end user is likely to dominate the market segment?
• Who are the key players in the AI in clinical trials market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?